Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy

Abstract

Regorafenib administered with a modified 2/1 schedule to patients who were aged ≥ 75 years and non-frail with treatment-refractory mCRC seems to be tolerable and achieve encouraging results in terms of PFS and OS.

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study

“…This compares favorably with similar reported studies. 13,15 Our subgroup analysis confirmed that performance status is one of the most important factors in regorafenib efficacy. All prior pivotal studies included only patients with PS 0 to 1, while one-third of our patients had PS more than one with a significant difference in PFS and OS (P = .0002 and .01, respectively) on both univariate analysis and multivariate analysis (P = .0097 and .0065, respectively).…”

“…Similar results in PFS have been reported with either retrospective single institution or small prospective studies. 13,14 The median OS in our cohort was 8 months, which also might be related to the short follow-up duration (median, 6.3 months). This compares favorably with similar reported studies.…”

“…In this prospective study, the PFS and OS for the entire group were 4.8 and 8.9 months, respectively. 13 The limitations of our study include its retrospective nature, the absence of toxicity evaluation, the small sample size, and the short median follow-up. On the other hand, its strength includes the multicenter nature and being the only study coming from this part of the world.…”

“…In this prospective study, the PFS and OS for the entire group were 4.8 and 8.9 months, respectively. 13…”

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD

“…Nevertheless, the incidence of adverse events related to regorafenib in patients over 80 years might require treatment adaptation. A recent alternative regimen of regorafenib 2 weeks-on treatment and 1 week off was evaluated in 23 fit older patients with mCRC who progressed after oxaliplatin and irinotecan based-chemotherapy [28]. The authors reported a DCR at 2 months of 52.2%, a PFS of 4.8 months and an OS of 8.9 months.…”